This article has been corrected. Please see J Manag Care Spec Pharm, 2017 Jul;23(7):725-734.
Economic Outcomes of First-Line Regimen Switching Among Stable Patients with HIV. Rosenblatt L, Buikema A, Seare J, Bengtson L, Johnson J, Cao F, and Villasis-Keever A. J Manag Care Spec Pharm. 2017 Jul;23(7):725-34.
The authors would like to make the following corrections to the above article:
Page 729, top of second column:
The text reporting use of initial ART regimens with a backbone of atazanavir/ritonavir did not include atazanavir/ritonavir-based regimens used by < 2% of the sample, which are not presented in Table 2. The frequency of all atazanavir/ritonavir-based regimens comparing switchers to nonswitchers should have been reported as (14.9% vs. 7.8%, P < 0.001), rather than (13.7% vs. 6.8%, P < 0.0 01).
The proportion of efavirenz-based regimens among non-switchers should be 67.1%, rather than 67.2%.
Page 730, first paragraph:
The P value comparing total ambulatory health care costs between switchers and nonswitchers should have been reported as 0.008, rather than 0.007.
Table 2: Footnote d should read “Only regimens used by ≥ 2.0% of the full study population are listed.”
Page 732: Several errors are located in the tabular data of Figure 2:
Total mean (standard deviation) pharmacy costs for nonswitchers in the full population should be given as 24,758b (9,725), not as 31,555b (33,470).
The standard deviation of ambulatory costs for switchers in the full population should be 14,103, not 14,203.
The significance indicators are missing from the values for ambulatory and emergency costs in the full population. These categories should each have a superscript c to indicate P < 0.05.
While the authors regret these errors, they do not affect the conclusions of the article.